Shares of ObsEva SA (NASDAQ:OBSV – Get Rating) have received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.33.
A number of research firms recently issued reports on OBSV. HC Wainwright cut ObsEva from a “buy” rating to a “neutral” rating in a report on Tuesday, August 30th. StockNews.com began coverage on ObsEva in a report on Thursday. They issued a “hold” rating for the company. Canaccord Genuity Group cut ObsEva from a “buy” rating to a “hold” rating and lowered their target price for the stock from $12.00 to $1.00 in a report on Monday, August 1st. Finally, Cantor Fitzgerald cut ObsEva from an “overweight” rating to a “neutral” rating in a report on Thursday, July 28th.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of OBSV. Virtu Financial LLC acquired a new position in shares of ObsEva in the first quarter valued at about $30,000. Banque Cantonale Vaudoise increased its holdings in shares of ObsEva by 143.2% in the first quarter. Banque Cantonale Vaudoise now owns 28,868 shares of the company’s stock valued at $44,000 after purchasing an additional 17,000 shares during the period. Banque Pictet & Cie SA acquired a new position in shares of ObsEva in the first quarter valued at about $83,000. XTX Topco Ltd increased its holdings in shares of ObsEva by 33.9% in the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after purchasing an additional 20,196 shares during the period. Finally, Millennium Management LLC purchased a new stake in shares of ObsEva in the second quarter worth about $192,000. 20.12% of the stock is owned by institutional investors and hedge funds.
ObsEva Price Performance
ObsEva (NASDAQ:OBSV – Get Rating) last posted its earnings results on Wednesday, August 17th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.06. The company had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, equities analysts anticipate that ObsEva will post -0.64 EPS for the current year.
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.
- Get a free copy of the StockNews.com research report on ObsEva (OBSV)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.